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Alzheimer’s Disease (AD) is the most common form of dementia, affecting approximately
36 million people worldwide. To date there is no preventive or curative treatment available
for AD, and in absence of major progress in therapeutic development, AD manifests a
concrete socioeconomic threat.The awareness of the growing problem of AD is increasing,
exempliﬁed by the recent G8 Dementia Summit, a meeting held in order to set the stage
and steer the compass for the future. Simultaneously, and paradoxically, we have seen key
players in the pharmaceutical industry that have recently closed or signiﬁcantly decreased
their R&D spending on AD and other CNS disorders. Given the pressing need for new
treatments in this area, other actors need to step-in and enter this drug discovery arena
complementing the industrial efforts, in order to turn biological and technological progress
into novel therapeutics. In this article, we present an example of a novel drug discovery
initiative that in a non-proﬁt setting, aims to integrate with both preclinical and clinical
academic groups and pharmaceutical industry to explore the therapeutic potential of new
concepts in patients, using novel biology, state of the art technologies and rapid concept
testing.
Keywords: Alzheimer’s disease, drug discovery and development, technology, pharmaceutical, non-profit,
collaborative research
INTRODUCTION
During the last 25 years the population of the world has increased
from 5.3 to almost 7.2 billion people (World Population Review,
2013). While an increased standard of living has resulted in
decreased mortality, a global increased awareness of healthy living
in combination with major progress in several areas of medicine
has also made signiﬁcant contribution to the increase in world
population. Indeed, the death caused by heart disease, stroke,
and cancer have decreased in the USA from 68% (1980) to 53%
(2010) (75 Years of Mortality in the United States, 1935–2010,
2012). In parallel with these encouraging numbers, another major
medical threat is emerging which could result in a major socioe-
conomic chaos in the absence of medical progress. The threat
is named Alzheimer’s Disease (AD). Worldwide, approximately 36
million people are diagnosed having dementia and 7.7million new
cases are discovered every year. AD is the most common cause of
dementia among the elderly and may contribute up to 60–70%
of all cases (World Health Organization, 2012). Currently there
is no curative or preventive treatment for the patients and only
a few drugs, which all provide limited symptomatic relief dur-
ing a relatively short time frame, are available. Age is by far the
largest risk factor for developing AD and the incidence increases
exponentially from about 1% of 65-year old people to 30% of
all 85-year-old people. With the current global increase in aver-
age lifespan, approximately 115 million people are estimated to
be suffering from AD in 2050. Besides the tremendous suffer-
ing for the affected individuals and their close relatives, the cost
for the society is estimated to be more than 200 billion USD in
2013 and 1200 billion USD by 2050 in the USA alone, a num-
ber that will put the healthcare system under enormous strain
(Alzheimer’s Association, 2013; World Alzheimer Report 2013,
2014).
Awareness, at the highest political level, of the emerging threat
of dementia was highlighted with the recent G8 summit on
dementia held in London in December 2013. The aim of the
meeting was to develop a coordinated global action on demen-
tia, and to shape an effective international response to dementia,
resulting in the communication of a declaration (G8 Demen-
tia Summit Agreements, 2013). This declaration included; “an
ambition to identify a cure, or a disease-modifying therapy, for
dementia by 2025.” This will be achieved by, e.g., signiﬁcantly
increasing the amount spent on dementia research, increasing
the number of people involved in clinical trials and studies on
dementia as well as develop an international action plan for
research. These efforts clearly state the sense of urgency in this
ﬁeld to move forward and for the research community to ﬁnd a
solution.
Dementia or senility as a concept or condition is a very old
phenomenon, referred to in medical texts since antiquity. Today,
we are aware of a large number of diseases that cause demen-
tia but AD represents the most common one (Ballenger, 2006;
Lane et al., 2012; Savonenko et al., 2012; Agis-Torres et al., 2014).
A major milestone in the history of AD took place approximately
100 years ago (1907), when the German neuropsychiatrist Alois
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Alzheimer ﬁrst described the key neuropathological hallmarks
of the disease (Hardy, 2006). During the examination of brain
sections derived fromhis patientAugusteD, amiddle-agedwoman
who suffered and died from dementia, Dr. Alzheimer discov-
ered so-called senile plaques and neuroﬁbrillary tangles in the
brain parenchyma. These were seminal ﬁndings, linking for the
ﬁrst time the form of dementia now called “Alzheimer’s disease,”
to speciﬁc pathological changes within the brain. However, the
recognition that dementia was a result of abnormal pathological
changes distinct from normal aging, did not really gain momen-
tum until the 1970s, with the birth of the cholinergic hypothesis.
A number of studies showed that, in AD brains, there was a par-
ticular loss of markers for cholinergic function as well as basal
forebrain cholinergic neurons early on in the disease pathol-
ogy (Francisa et al., 1999). These discoveries fueled an intense
research effort to ﬁnd drugs that could target cholinergic dys-
function and today three out of the four commonly prescribed
drugs for AD (donepezil, rivastigmine and galantamine) are so-
called cholinesterase inhibitors (Greenberg et al., 2013). These
drugs inhibit the degradation of acetylcholine in the synaptic
cleft, thereby sustaining the action of acetylcholine with a subse-
quent improvement in cognitive function in the patient. However,
the underlying neurodegenerative cascade is not affected by these
treatments, and the effect is thereby limited in time due to the
continuous loss of cholinergic neurons and thus acetylcholine
production in the disease. Moreover, gastrointestinal side effects,
relating to muscarinic receptor engagement in the gut, as well as
headache and effects on heart rate are also dose-limiting factors
for the patients. The fourth described drug for AD is memantine,
a weak NMDA receptor antagonist, prescribed for moderate to
severe AD. Similar to the acetylcholinesterase inhibitors, meman-
tine provides symptomatic relief for a limited time period, but
is not believed to alter the neurodegenerative cascade of the
disease.
ALZHEIMER’S DISEASE – NAVIGATION THROUGH
COMPLEXITY
Although the progress in the drug development for AD has been
limited over the last 30–40 years, signiﬁcant progress has been
made in understanding the mechanisms behind the development
of AD, e.g., the pathology, neurobiology, and genetics (Corbette
et al., 2012; Dunkel et al., 2012; Kepp, 2012; Greenberg et al., 2013).
Among these ﬁnding were the discoveries of the amyloid beta
peptide (Aβ) and the tau protein, the principal components of
senile plaques and neuroﬁbrillary tangles, respectively. Further-
more, researchers were also able to identify more than 200 disease
causing mutations localized to three genes directly involved in Aβ
generation as well as unravel some of the molecular machinery
and underlying mechanisms of Aβ production. Combined, these
discoveries provided a strong rationale for a better understanding
of the neurotoxic role of Aβ in AD and for the development of Aβ
amyloid-directed therapies. Accordingly, during the last 15 years,
both active and passive vaccines targeting Aβ as well as several
inhibitors and modulators targeting the aggregation or synthesis
of Aβ peptide has been developed and tested in AD clinical trials.
In addition, a large number of other drug candidates exhibiting
a range of different non-Aβ targeting therapeutic mechanism of
BOX 1 | Some key challenges to be addressed in the develop-
ment of novel therapeutics for Alzheimer’s disease.
Identify and link novel pathways and biomarkers to AD progres-
sion.
Improved preclinical modeling of disease relevant pathology.
Engaging multiple targets might be required (polypharmacology)
and thereby using a multi-drug regimen.
Establish and conduct conclusive proof-of-concept (PoC) studies.
Use appropriate patient inclusion criteria in clinical trials.
Achieve sufﬁcient CNS exposure/target engagement of the drug.
Establish appropriate biomarkers and/or surrogate markers for
target engagement.
Establish surrogate markers for clinical effect to shortened the
length of clinical trial.
Improved clinical endpoints, e.g., more sensitive and relevant
cognitive measures.
Avoid safety issues due to chronic, systemic exposure of the
drug.
Feedback to discovery from clinical PoC to reﬁne hypothesis and
improve research models.
Handle potential drug–drug interactions (patient population often
on other medications).
action have been tested clinically. These include those that are
primarily aiming for a symptomatic effect by increasing synaptic
activity, e.g., compounds that interact with nicotinic, histaminer-
gic, and serotonergic receptors (Misra and Medhi, 2013). Despite
that many of these drug candidates have shown promising effect
in preclinical models, the results from clinical trials have been
disappointing, and no new drugs after the acetylcholine esterase
inhibitors and the NMDA blocker memantine have made it all the
way to the market. It is well recognized that drug discovery in the
AD ﬁeld has been hampered by the failure of preclinical models
to recapitulate some of the key features of the AD pathogenesis
(Savonenko et al., 2012). The use of these models to unravel the
complex features of the neurodegenerative cascade inAD,aswell as
translational tools in, e.g., dose prediction studies, have therefore
been limited.
The reasons for the clinical failures are likely many, and dif-
fer among the drug candidates tested (Mangialasche et al., 2010;
Schneider et al., 2014). Major contributors to the general lack of
success include insufﬁcient target exposure to achieve a clinically
meaningful effect, that the drug was not tested long enough, safety
issues due to on- and off-target pharmacology and/or that the dis-
ease context was not appropriate for the therapeutic mechanism
explored (see Box 1). The latter stems from recent progress in
biomarker research, which has shown that the AD pathological
cascade start early and takes place over decades prior to symp-
toms onset, and where Aβ amyloidosis dominates at early stages
followed by more overt and outbread neuronal dysfunction and
neuronal degeneration, implicating other pathogenic drivers of
disease, once the disease becomes symptomatic and progresses
into severe stages of dementia (Sperling et al., 2011). Therefore, a
therapy tailored for a speciﬁc component of the AD pathogenic
cascade may have to be given to patients at a speciﬁc stage of
the disease in order to be efﬁcacious. The recent development
of speciﬁc radiopharmaceutical diagnostic tools for PET imaging
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Aβ-amyloid plaque density (e.g., ﬂorbetapir and ﬂorbetaben) has
been extremely useful in assessing amyloid load in patients at var-
ious stages of the disease (Herholz and Ebmeier, 2011). Thanks
to these new methods with improved resolution combined with
improvements in biomarker monitoring, the characterization and
diagnosis of patients suspected to be suffering from AD pathogen-
esis have improved. Interestingly, such analyses have revealed that
as many as 25–30% of the patients included in recent trials with
therapeutic antibodies targeting Aβ amyloidosis were in fact neg-
ative for Aβ-amyloid in their brains (Doody et al., 2014; Salloway
et al., 2014). These observations highlight the need to design trials
where a lot of emphasis is put on the patient inclusion criteria in
order to increase the odds to get meaningful clinical response of
the therapeutic compound and/or mechanism tested.
FUTURE IDEAS TOWARDS NOVEL AD THERAPEUTICS
THE POTENTIAL OF ACADEMIC DISCOVERIES IN AD
The pharmaceutical industry (pharma) is currently under pres-
sure from a range of different challenges in its environment,
e.g., increased R&D costs, patent cliffs causing a major loss of
income, high attrition of projects in the portfolio, increasing
cost-constraints in the healthcare system mandating generics and
parallel import, and not the least, more demanding regulatory
requirements (Kola andLandis,2004; Cuatrecasas,2006; Schachter
and Ramoni, 2007; Munos, 2009; Paul et al., 2010; Scannell et al.,
2012; Slusher et al., 2013). In our view, an attractive alternative to
the current way of working, as well as a way to offer a potential
solution to the gaps in drug discovery and development pipelines,
is to increase the research efforts in non-proﬁt biopharmaceuti-
cal research institutions, such as universities and private research
institutes, where creative and innovative science is not severely
restricted by commercial objectives, but where novel hypothe-
sis can be tried with industrial stringency in a dedicated way.
These types of smaller research units could make signiﬁcant con-
tributions to the ﬁeld since it is well recognized that small- and
medium-sized biotechnological companies have been more suc-
cessful than big pharmaceutical companies in moving candidate
substances through the pipeline, and in particular,more successful
in producing biological products, such as monoclonal antibodies,
vaccines, and peptides (Munos, 2009). Non-proﬁt organizations
are well suited to address areas of large unmet need in rare CNS-
disorders classiﬁed as orphan diseases. These diseases are, on the
whole, not commercially blockbusters and, thus, research funded
by philanthropists and public sources will be key to encourage
work in these areas. It is also likely that certain therapeutics
developed for an orphan indication may turn out to be efﬁca-
cious in related disorders that share certain common features or
principles of pathogenesis. The availability of clinically validated
drugs is extremely valuable, and repositioning of existing drugs for
novel indications opens up novel exciting possibilities to accelerate
therapeutic development in complex CNS disorders such as AD.
Today when many major pharmaceutical companies are down-
sizing their R&Defforts in theCNS area (Alzheimer’sDrug Failure:
implication for Future R&D in Neuroscience, 2012), they have a
strong need to get access to outside expertise in speciﬁc scien-
tiﬁc areas such as for the identiﬁcation of novel targets, increasing
the knowledge in certain target families, advancing new platform
technologies for preclinical and clinical research, improving the
diagnosis of disease, pharmacology and safety biomarker devel-
opment, access to human cells and tissues for target validation, as
well as how to perform earlier proof-of-mechanism (PoM) and
proof-of-concept (PoC) studies, including clinical safety stud-
ies. Some of this will of course be possible through established
collaborations between the pharmaceutical industry and third par-
ties such as contract research organization (CRO) and academia,
such an example is the Dominantly Inherited Alzheimer Net-
work (DIAN, established in 2008), which test diagnostics and
novel treatments in a speciﬁc patient population. Although many
CROs now provide customers with various non-regulatory in vitro
and in vivo experiments during early discovery, their main activ-
ities are regulatory-driven (in accordance with good laboratory
practice (GLP) in later phases of drug development). How-
ever, we see an attractive alternative in non-proﬁt biomedical
research institutions, where scientiﬁc collaborations can be based
on a close interaction rather than contracting. This collaborative
network/partnership will facilitate a closer preclinical-to-clinical
translation at the target, model, assay, substance, patient and clini-
cal testing levels as well as in the development of new technologies.
Innovation and progress driven in these areas by such constel-
lations will certainly accelerate therapeutic development in AD,
and thereby attract increased interest from the big pharmaceutical
companies, given that the potential return of investment would be
substantial.
AlzeCure FOUNDATION – AN EXAMPLE
AlzeCure is a Swedish-based non-proﬁt drug discovery founda-
tion, whose aim is to develop novel therapeutics for AD and
related disorders (see Box 2 and Figure 1). This new organiza-
tion was founded in 2013 by former AstraZeneca scientists with
more than 30 years of experience from the CNS drug discovery
and development area. The team exhibits complementary skills
and expertise, frommedicinal chemistry, screening, in vivo transla-
tional/biomarker competence toADME and clinical development.
The strategy of AlzeCure Foundation (“AlzeCure”) is to use its
wide experience and international network in the Alzheimer ﬁeld
to run collaborative projects with external expertise that has the
potential to deliver real value for the patients. The team focuses
on areas of research and development, which are of urgent need
of innovative solutions, such as mechanistic diversity, preclinical
models, drug delivery, clinical testing, and biomarker monitor-
ing. We are convinced that rapid feedback to the drug discovery
process from positive or failed PoC studies are essential in order
to improve our understanding and to progress the development
of efﬁcacious therapeutics. Such backtranslation is also crucial in
order to accelerate the development of follow-on compounds that
address the same mechanism, but have improved drug-like char-
acteristics, or to identify related mechanistic targets that will lead
to new clinical studies. History has proven that there is a synergy
between technology and biology innovation and in that interface,
exciting discoveries take place that can result in novel products
with a remarkable potential. Similarly, we strongly believe that
technology breakthroughs will contribute signiﬁcantly to speed
up and improve the development of novel therapies in major CNS
disorders.
www.frontiersin.org May 2014 | Volume 5 | Article 102 | 3
Lundkvist et al. The battle of Alzheimer’s Disease
BOX 2 | Strategies of the AlzeCure foundation.
Strong focus on both innovative drug discovery and clinical
testing.
Use unique technology for drug administration.
Develop novel technology for biomarker monitoring.
Explore new therapeutic mechanisms and principles.
Develop of combination treatments affecting more than one
biological pathway.
Test old marketed drugs or early closed candidate drugs on novel
AD-targets.
Run phenotypic screens with well-deﬁned pathological end-
points.
Collaborate with academic and industrial expertise to comple-
ment in-house expertise and capabilities.
Design early PoM and PoC clinical studies to test new hypothe-
sis.
Optimize patient selection for earlier clinical safety and efﬁcacy
studies, based on qualiﬁed clinical biomarkers.
The laboratories of AlzeCure are located in direct vicinity to
biotech companies and Karolinska Institute Alzheimer Research
Center with academic groups of leading experts in neurobi-
ology, preclinical and clinical laboratories with a long track
record in AD translational research and in clinical trials. The
strategic localization of AlzeCure has resulted in face-to-face
interactions with these institutions and disciplines on a regu-
lar basis, which is a strong enabling factor for effective project
progression and success. The non-proﬁt nature of AlzeCure has
turned-out to facilitate the establishment of joint efforts with
both academia and industry and attract alternative funding.
Today, AlzeCure manages several collaborations with interna-
tional academic experts in both preclinical and clinical research.
AlzeCure collaborates with several biotech companies, which
provide unique chemistry and technology that in combination
with neuronal screening assays based on induced pluripotent
stem cells (iPS) and phenotypic endpoints, provide the basis for
novel drug discovery. The most advanced collaboration aims at
a novel way of administering therapeutic tau-directed antibod-
ies to the brain, in order to increase target engagement and
thereby therapeutic activity1. Tau is emerging as a new impor-
tant molecular target in AD, and several anti-tau antibodies are
rapidly approaching clinical trials. However, a major challenge
with peripheral administration of antibodies is to reach the tar-
get in the brain to a sufﬁcient extent. AlzeCure is together with
NsGene, a Denmark and US-based biotechnology company, and
Peter Davies (Feinstein Institute) evaluating a new concept to
deliver therapeutic antibodies to the brain, using a novel pro-
prietary Brain-Repair technology platform developed by NsGene
(Lindvall and Wahlberg, 2008). The Brain-Repair platform is an
implant comprised a semi-permeable hollow ﬁber containing a
human cell line, which is engineered to locally produce thera-
peutic proteins of choice that diffuse into the target tissue. The
implant has been clinically validated in patients diagnosed with
AD through collaboration between NsGene and the Karolinska
1See www.alzecure.org
Institute (Eriksdotter-Jönhagen et al., 2012). An opportunity with
this device would be to more rapidly test the hypothesis in a
PoC study in a well-deﬁned tauopathy patient population for
an orphan indication, before entering large expensive phase III
trials. In this manner, we foresee getting both the technology,
therapeutic mode of action, clinical effect, and safety evalu-
ated, in an effective and conclusive manner within a shorter
time frame compared to common standards of clinical testing in
AD. Obviously the Brain-Repair implant also offers a very excit-
ing concept to rapidly test other therapeutic hypothesis beyond
tau-directed antibodies, and illustrates a concrete example where
technology innovation together with new biology form a novel
avenue for therapy development applicable for multiple CNS
disorders.
A co-initiator and also major ﬁnancial contributor to AlzeCure
is the Swedish Alzheimer foundation, a charity organization. This
type of direct ﬁnancial commitment and interest in drug discov-
ery and development in complex disorders such as CNS diseases
from charity organizations is novel and may point to a new path
for future organizations. In addition, the Swedish Brain Power
program is sponsoring AlzeCure with two Ph.D. positions, which
are highly integrated into the academic labs thereby providing
the basis for a strong two-way communication between academic
science and industrial development, which is of high mutual inter-
est. Given the declining interest from many big pharmaceutical
companies and venture capitalists alike in CNS disorders and the
pressing need for new medications, initiatives like these are new
ways of trying to directly stimulate drug discovery efforts in an
area of great medical need. Interestingly, in line with the inten-
tion of AlzeCure, Alzheimer Research UK announced at the end
of 2013 that they were to initiate a Drug Discovery Institute con-
sisting of leading academic groups in the UK that will have close
access to both preclinical and clinical research units and hospitals
specialized in neurodegenerative diseases that cause dementia.
CONCLUSION
The problem we as a society are facing is of unseen proportions,
highlighting the need of concerted actions at multiple levels of
society. A ﬁrm political leadership paired with a well-designed
regulatory framework and strong incentives for academia, the
industry and the health care providers is needed in order to
consolidate the resources and optimize the process required to
make rapid and signiﬁcant progress in therapeutic development
for AD. In this light it may seem paradoxical that several major
industrial actors, such as AstraZeneca, Bristol-Myers Squibb,
GlaxoSmithKline, and Novartis have either abandoned the neuro-
science therapeutic indication as such, or heavily decreased their
head count within this area (Abbot, 2011). However, other com-
panies, e.g., Eli Lilly, Roche, Pﬁzer have continued a strong interest
in the area and are closely collaborating the regulatory agencies,
which recently resulted in a Guidance for Industry from FDA on
Alzheimer’s disease: Developing drugs for the treatment of early
stage disease (U.S. Food and Drug Administration, 2013). The
medical need is however still unmet and rapidly growing, thus
something radical needs to be done. For a start, we believe that
new initiatives such as the AlzeCure Foundation and Drug Dis-
covery Alzheimer Research UK group, both being non-proﬁt and
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FIGURE 1 | This cartoon illustrates the proposed AlzeCure business
(A) and strategy models (B) to develop new therapies and
medicinal technology products, highlighting the proof-of-mechanism
(PoM)/proof-of-concept (PoC) as an important milestone in drug
discovery and development process. Traditionally, in order to reach
clinical PoM and PoC with “standard peripherally administered” drug
candidates in a chronic condition, the drug needs to display key and
optimized features including adsorption, distribution, metabolism,
tolerability, and BBB permeability, in addition to its desired
pharmacology and safety. This is seldom achieved despite signiﬁcant
medicinal chemistry, an effort that takes place over a very long time in
the discovery phase. As a consequence, many suboptimal compounds
are being explored in the clinic without being able to test the
hypothesis they were aimed for in a conclusive manner. Building the
need to get strong evidence for PoM/PoC, including close collaboration
with international academic preclinical research, utilizing new Translational
enabling technologies into the discovery process, is crucial. To reduce
the attrition due to lack of efﬁcacy and safety, it is important to design
the ﬁrst clinical trials, a design based on appropriate animal models,
pharmacokinetic/pharmacodynamic modeling, and utilizing biomarkers and
surrogate markers, in the “right patients,” to facilitate that the molecular
target is being hit at an expected concentration to give the anticipated
physiological response without safety issues. Optimally, the PoM/PoC
clinical trials are conducted at Clinical Trial Centers that are closely
involved in the discovery research. It is also important to have a rapid
feed-back to the drug discovery process from positive or failed PoM/PoC
studies to improve the understanding of mechanisms, and to accelerate
the development of follow-up compounds that address the same
mechanism, but with improved drug-like characteristics or to identify
related mechanistic targets that will lead to new clinical studies.
taking full advantage of the open-minded academic style of work-
ing with the stringent and goal-oriented industrial R&D, have the
promise of being more innovative and effective unleashing the
potential of academic discoveries and providing an exciting new
framework for the long-termobjective to deliver effective therapies
to the beneﬁt of the patients.
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